Wen, F., Lin, T., Tan, P., Deng, J., Ren, M., Zhang, M., Zheng, X., Zhang, P., Shen, Y. (2025). A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.795